Uromodulin levels are decreased in urine during acute tubular necrosis but not during immune rejection after renal transplantation

1993 ◽  
Vol 84 (2) ◽  
pp. 243-246 ◽  
Author(s):  
P. Jeremy McLaughlin ◽  
Atsushi Alkawa ◽  
Helen M. Davies ◽  
Richard G. Ward ◽  
Ali Bakran ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Tumour Necrosis Factor ◽  
Acute Tubular Necrosis ◽  
Tumour Necrosis ◽  
Graft Function ◽  
Enzyme Linked Immunosorbent Assay ◽  
Immune Rejection ◽  
High Affinity ◽  
Tubular Necrosis ◽  
Necrosis Factor

1. Uromodulin, an immunosuppressive glycoprotein found in urine, is a high-affinity binding ligand for certain cytokines, including tumour necrosis factor. 2. Its occurrence in urine was monitored after renal transplantation to investigate whether this simple urine test might differentiate common early causes of graft failure: acute immune rejection and acute tubular necrosis. 3. Diluted urine was assayed for uromodulin using a sandwich enzyme-linked immunosorbent assay. When graft function failed due to acute tubular necrosis, urinary uromodulin levels were significantly depressed compared with levels in urine produced during biopsy-proven acute immune rejection episodes (P < 0.01) or during periods of stable graft function (P < 0.02). This suggests that urinary levels of uromodulin may reflect tubular damage rather than other causes of graft functional failure. 4. The cytokine tumour necrosis factor, which binds with high affinity to uromodulin, was found in 30% of urine samples in association with immune rejection episodes, but not during acute tubular necrosis. However, the presence of urinary tumour necrosis factor was not related to levels of uromodulin in the same sample.

scholarly journals Cytokine profile after rubella vaccine inoculation: evidence of the immunosuppressive effect of vaccination

2003 ◽  
Vol 12 (4) ◽  
pp. 203-207 ◽  
Author(s):  
Alexander L. Pukhalsky ◽  
Galina V. Shmarina ◽  
Maria S. Bliacher ◽  
Irina M. Fedorova ◽  
Anna P. Toptygina ◽  
...  
Keyword(s):  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Cytokine Production ◽  
Enzyme Linked Immunosorbent Assay ◽  
Tumour Necrosis Factor Α ◽  
Lymphocyte Response ◽  
Rubella Vaccine ◽  
Live Virus ◽  
Factor Α ◽  
Necrosis Factor

Background:Immunization with live virus vaccines may cause an immunosuppression with lymphopaenia, impaired cytokine production and defective lymphocyte response to mitogenes. These abnormalities were described in subjects vaccinated against measles. This study was performed to analyse the host immune response related to immunosuppression in subjects vaccinated with live attenuated rubella vaccine.Methods:Eighteen schoolgirls, aged 11-13 years, were vaccinated with live attenuated rubella vaccine Rudivax®. Before immunization, and 7 and 30 days after, peripheral blood was collected. Cellular fractions were subjected to flow cytometric analysis, and the lymphocyte response to phytohaemagglutinin was investigated. Plasma samples were analysed for cytokines (interleukin (IL)-4, IL-10, tumour necrosis factor-α, and interferon-γ) by enzyme-linked immunosorbent assay techniques.Results:On day 7 after vaccination, the number of each lymphocyte subset was decreased; however, only for CD3 and CD4 lymphocytes has a significant reduction been shown. On the contrary, tumour necrosis factor-α and IL-10 levels markedly increased and amounted to its maximum on day 30. Simultaneously, a significant reduction in plasma interferon-γand a profound decrease of the lymphocyte response to phytohaemagglutinin were shown. The changes were accompanied with marked elevation of plasma IL-4.Conclusions:Our data indicate that the vaccination with live attenuated rubella vaccine results in moderate but sustained immune disturbance. The signs of immunosuppression, including defective lymphocyte response to mitogene and impaired cytokine production, may persist for at least 1 month after vaccination.

Vascular endothelial growth factor D is a biomarker of fluid overload in haemodialysis patients

2020 ◽  
Author(s):  
Seraina von Moos ◽  
Stephan Segerer ◽  
Andrew Davenport ◽  
Malha Sadoune ◽  
Kerem Gerritsen ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Fluid Overload ◽  
Enzyme Linked Immunosorbent Assay ◽  
Vascular Endothelial ◽  
Factor C ◽  
Endothelial Growth Factor ◽  
Necrosis Factor

Abstract Background Improved understanding and assessment of the complex physiology of volume regulation in haemodialysis (HD) patients are required to improve patient care and reduce mortality associated with fluid overload (FO). Methods We searched for FO-related biomarkers among 184 peptides associated with cardiovascular disease in a cohort of 30 HD patients. First, we assessed the direct impact of HD on the peptides of interest by comparing plasma concentrations before and after treatment. Then, we compared cardiovascular peptide profiles between patients with and without FO as defined by bioimpedance analysis (BIA). The plasma concentration of selected candidate biomarkers for FO was determined by enzyme-linked immunosorbent assay (ELISA) and correlated with previously described FO-related clinical and laboratory parameters. For validation, results were confirmed in an independent cohort of 144 HD patients. Results We found seven peptides positively [NT-proBNP, B-type natriuretic peptide (BNP), vascular endothelial growth factor D (VEGFD), tumour necrosis factor-related apoptosis-inducing ligand receptor 2, growth differentiation factor 15, tumour necrosis factor ligand superfamily member 13B, chitinase-3-like protein 1] and five negatively (leptin, renin, epidermal growth factor receptor, interleukin-1 receptor antagonist, myeloblastin) correlated to FO. In addition to natriuretic peptides, VEGFD emerged as third peptide highly correlated with BIA (ρ = 0.619, P &lt; 0.0001). In line with this, VEGFD concentration verified by ELISA correlated with BIA, BNP and soluble CD146 but not with vascular endothelial growth factor C (VEGFC). Notably, levels of VEGFD were unrelated to cardiac systolic function (P = 0.63), contrary to BNP (P = 0.0003). Finally, we observed that 1-year all-cause mortality was higher in patients with high BNP (P = 0.0002), FO (defined by BIA, P = 0.04) and high VEGFD (P = 0.02), but not with high VEGFC (P = 0.48). Conclusion VEGFD is a novel FO-related biomarker with unique diagnostic and prognostic properties.

scholarly journals Role of soluble gp130 in the tumour necrosis factor-α expression and its production by peripheral blood mononuclear cells

2003 ◽  
Vol 12 (6) ◽  
pp. 355-359
Author(s):  
E. Jablonskaca ◽  
W. Puzewska ◽  
M. Marcinczyk ◽  
J. Jablonski
Keyword(s):  
Tumour Necrosis Factor ◽  
Interleukin 6 ◽  
Peripheral Blood ◽  
Tumour Necrosis ◽  
Enzyme Linked Immunosorbent Assay ◽  
Tumour Necrosis Factor Α ◽  
Tnf Α ◽  
Factor Α ◽  
Necrosis Factor ◽  
Soluble Gp130

Background:In our previous study we found that rhsIL-6R, along with recombinant human interleukin-6, plays a regulatory role in the immune response by modulating the tumour necrosis factor-α (TNF-α) expression and its production by peripheral blood mononuclearcells (PBMC). We also suggested that sIL-6R with IL-6 secreted by human PMN (neutrophils) influenced the TNF-α expression and its production by autologous PBMC.Aims:Since soluble gp130 (sgp130) is a natural inhibitor for sIL-6R/interleukin-6 responses, in the present study we estimated an effect of exogenous recombinant human sgp130 and sgp130 secreted by PMN on the TNF-α expression and its production by PBMC.Methods:Cells were isolated from whole blood of healthy persons. The PMN were cultured in 96-well plates for 1 h at 37°C in a humidified incubator with 5% CO2. After the incubation, the culture supernatant of PMN was removed and added to the PBMC. PBMC were incubated for 1 h at 37°C in the same conditions. Cytoplasmic protein fractions of PMN and, for comparative purpose of PBMC, were analysed for presence of sgp130 by western blotting with the use of monoclonal antibody capable of detecting this protein. In the culture supernatants of PMN we examined the concentrations of sgp130 by human enzyme-linked immunosorbent assay. TNF-α was measured at the protein levels as well as the mRNA levels.Results and conclusions:The present results revealed that exogenous recombinant human sgp130 modulates the TNF-α expression and production by PBMC. In contrast, we did not find any effect of sgp130 secreted by PMN on the TNF-α expression and its production by autologous PBMC.

Role of salivary tumour necrosis factor α in HIV-positive patients with oral manifestations

2007 ◽  
Vol 18 (8) ◽  
pp. 565-569 ◽  
Author(s):  
Tomoaki Ino ◽  
Akio Tada ◽  
Akira Tominaga ◽  
Yasuo Komori ◽  
Hiroshige Chiba ◽  
...  
Keyword(s):  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Enzyme Linked Immunosorbent Assay ◽  
Oral Manifestations ◽  
Tumour Necrosis Factor Α ◽  
Cd4 Cells ◽  
Tnf Α ◽  
Factor Α ◽  
Hiv 1 ◽  
Necrosis Factor

In HIV-1-infected patients, oral manifestations such as recurrent apthous ulcers are often seen. A total of 29 HIV-infected patients were examined to determine salivary tumour necrosis factor α (TNF α) concentrations by enzyme-linked immunosorbent assay, the amount of HIV-1 RNA copy by Amplicor HIV-1 Monitor test, number of CD4 cells by flow cytometry and oral manifestations by oral examination. TNF α concentration was significantly correlated with the amount of HIV-1 RNA, however, not with the number of CD4 cells in HIV-1-infected patients. Further, patients with oral manifestations showed significantly higher concentrations of TNF α in saliva and HIV-1 RNA copies in serum than those without oral manifestations. Following recovery from oral ulcers, TNF α concentration was decreased by half to 20 times lower than the level of that during ulcer incidence. Our results suggest that salivary TNF α is a good indicator for oral manifestations and HIV RNA amounts in HIV-1-infected patients.

Serum soluble tumour necrosis factor related apoptosis-inducing ligand level and peripheral eosinophil count in patients with nasal polyposis

2015 ◽  
Vol 129 (3) ◽  
pp. 250-253 ◽  
Author(s):  
A Bisgin ◽  
H Eyigor ◽  
U Osma ◽  
M D Yilmaz ◽  
A D Yalcin
Keyword(s):  
Tumour Necrosis Factor ◽  
Eosinophil Count ◽  
Tumour Necrosis ◽  
Nasal Polyposis ◽  
Enzyme Linked Immunosorbent Assay ◽  
Blood Eosinophil ◽  
Clinical Markers ◽  
Significant Difference ◽  
Computed Tomography Scans ◽  
Necrosis Factor

AbstractBackground:Nasal polyposis is one of the most common inflammatory pathologies of the nasal cavity. Eosinophilic inflammation plays an important role in the pathogenesis. This study aimed to investigate soluble tumour necrosis factor related apoptosis-inducing ligand levels and eosinophil count in nasal polyposis patients.Methods:The study was performed on 24 adult nasal polyposis patients and 24 age-matched healthy individuals. The patients had not received any medical or surgical treatment. Pre-operative computed tomography scans were assessed using the Lund–MacKay grading system, and soluble tumour necrosis factor related apoptosis-inducing ligand levels were measured with a sandwich enzyme-linked immunosorbent assay.Results:Compared with controls, eosinophil levels in nasal polyposis patients were increased (p = 0.024), but there was no significant difference in soluble tumour necrosis factor related apoptosis-inducing ligand levels (p = 0.529). The Lund–Mackay mean grading was 12.43 ± 6.9. There was no correlation between soluble tumour necrosis factor related apoptosis-inducing ligand level and Lund–Mackay grading and eosinophil count.Conclusion:There was no relationship between soluble tumour necrosis factor related apoptosis-inducing ligand level and blood eosinophil or clinical markers; however, soluble tumour necrosis factor related apoptosis-inducing ligand level remains of interest for future studies.

Improvement in sensitivity of enzyme-linked immunosorbent assay for tumour necrosis factor

1990 ◽  
Vol 68 (1) ◽  
pp. 51-55 ◽  
Author(s):  
P. Jeremy McLaughlin ◽  
Ngaire J. Elwood ◽  
Lanny T. Ramadi ◽  
Marie R. Pica ◽  
Ian F. C. McKenzie
Keyword(s):  
Tumour Necrosis Factor ◽  
Immunosorbent Assay ◽  
Tumour Necrosis ◽  
Enzyme Linked Immunosorbent Assay ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document